Alfadiag’s Post

The Future of Liquid Biopsies: Alone or Combined? Explore the potential of liquid biopsies in cancer screening. This video discusses the advantages of combining liquid biopsies with traditional morphology methods and highlights the importance of a comprehensive approach for accurate diagnosis. Join us in envisioning the future of cancer detection! #LiquidBiopsy #CancerScreening #MedicalInnovation #HealthTech #Diagnostics #Morphology #CancerResearch #BiopsyTesting #FutureOfMedicine #HealthcareInsights

📢 Join us on November 27th at 6pm CET for a virtual debate on surgical options for early-stage lung cancer following definitive pathology. 📝 The expert faculty will dive into the latest evidence, discuss clinical outcomes, explore patient considerations and encourage critical thinking and lively debate. 👉 Register here: https://lnkd.in/eguV-nSW #JNJInstitute #mycompany #LungCancerAwarenessMonth

This week: Castle will present NEW DATA supporting its TissueCypher Barrett's Esophagus test (TSP-9) at the American Foregut Society (AFS) 2024 Annual Meeting 9/25-29 in Denver. Oral abstract will share data showing that TissueCypher alone, compared to combining the test’s results with a patient’s clinicopathologic risk factors, like age and pathology diagnosis, is the strongest predictor of progression to esophageal cancer. Poster will highlight ability of the test to guide important patient management decisions, including upstaging care for high-risk patients and supporting long-interval surveillance for patients at low risk of progression. Highlights/details: https://hubs.la/Q02QN_sS0

The September Issue of Today's Clinical Lab is here! 🔬 Dive into the latest on cancer pathology, cutting-edge research, and breakthrough technologies shaping the future of diagnostics. 🧬 👀 Explore expert insights and stay ahead in the world of clinical laboratories. Check out the full issue now! September Issue 👉 https://bit.ly/4ee7XeG #ClinicalLab #CancerPathology #Diagnostics #LaboratoryScience #HealthcareInnovation

This week: Castle will present NEW DATA supporting its TissueCypher Barrett's Esophagus test (TSP-9) at the American Foregut Society (AFS) 2024 Annual Meeting 9/25-29 in Denver. Oral abstract will share data showing that TissueCypher alone, compared to combining the test’s results with a patient’s clinicopathologic risk factors, like age and pathology diagnosis, is the strongest predictor of progression to esophageal cancer. Poster will highlight ability of the test to guide important patient management decisions, including upstaging care for high-risk patients and supporting long-interval surveillance for patients at low risk of progression. Highlights/details: https://hubs.la/Q02QNNW60

Oncology programs and the advancement of cancer care require precise clinical data. IMO Health offers specialized #oncology terminology, such as ICD-O-3.2, to help clinical teams capture critical details. Our #terminology enables documentation for topography, histology, and morphology, making clinical data more usable for research and helping to improve patient outcomes. Learn how IMO Health solutions can empower better cancer care: https://bit.ly/3C5WHTw Prefer a direct conversation? Chat with one of our experts to explore how this specialized terminology can improve your clinical data: https://bit.ly/40iP1rq #OncologyCare #CancerCare #ValueBasedCare #ClinicalResearch

"Exploring the intricacies of PET/CT imaging and its impact on cancer diagnostics and treatment! Delving into the fusion of functional and anatomical imaging, this technology provides crucial insights into tumor metabolism, guiding personalized care and improving outcomes. Excited to contribute to advancements in precision oncology and patient care. #MedicalImaging #PETCT #Oncology #Radiology #CancerCare #PrecisionMedicine"

📝We share the #Article "Deep Learning for the Pathologic Diagnosis of Hepatocellular Carcinoma, Cholangiocarcinoma, and Metastatic Colorectal Cancer" 👥by Hyun-Jong Jang et al. The Catholic University of Korea 📌Link here: https://lnkd.in/d3r4wdBs Keywords: deep learning; pathology; hepatocellular carcinoma

Oncology programs and the advancement of cancer care require precise clinical data. IMO Health offers specialized #oncology terminology, such as ICD-O-3.2, to help clinical teams capture critical details. Our #terminology enables documentation for topography, histology, and morphology, making clinical data more usable for research and helping to improve patient outcomes. Learn how IMO Health solutions can empower better cancer care: https://bit.ly/3C5WHTw Prefer a direct conversation? Chat with one of our experts to explore how this specialized terminology can improve your clinical data: https://bit.ly/40iP1rq #OncologyCare #CancerCare #ValueBasedCare #ClinicalResearch

👉🏼 Large language model enhances understanding of pathology reports in colorectal cancer 🤓 Anqi Wang 👇🏻 https://lnkd.in/eyWwMxFS 🔍 Focus on data insights: - 📊 LLM provides credible answers to common pathology questions from colorectal cancer pathology reports. - 🚀 The interactive system allows users to upload standard pathology reports as JPG images, facilitating improved communication. - 🏷️ Evaluation metrics